HSE agrees to reimburse immunotherapy drugs for skin cancer patients 

Adjuvant immunotherapy drugs for stage three melanoma patients have been approved for reimbursement by the HSE. File picture.

Adjuvant immunotherapy drugs for stage three melanoma patients have been approved for reimbursement by the HSE.

This comes after two-and-a-half years of campaigners highlighting the unequal treatment of public and private patients who have stage three melanoma, or skin cancer.